RE:Seagen deprioritizes ADC that previously was $1.6 Bln dealThis development to drop the further development of the antibody-drug conjugate (ADC) reveals that any current licensing agreement for a single indication is worth US$600 million + a US$1 Billion investment in the stock of the company.
A further investment of US$2.6 Billion was to be a follow-up milestone payment in this upfront payment + stock purchase + follow-up bio-buck deal.